Will the stock go down if the business does not make money?
Just because a business does not make any money, does not mean that the stock will go down. Indeed, BELLUS Health...
Will blo outperform or underperform the S&P 500?
Vote “Outperform” if you believe BLO will outperform the S&P 500 over the long term. Vote “Underperform” if you believe BLO will underperform the S&P 500 over the long term. You may vote once every thirty days.
Does September have a bad reputation for stocks?
September may have a bad reputation for stocks, but one top strategist just hiked his S&P 500 year-end target anyway Affirm (NASDAQ:AFRM) set a Low Bar for its Q4 Report. Here is What Will Actually Drive High Growth
Who are Cannabix Technologies' key executives?
Cannabix Technologies' management team includes the following people: Mr. Ravinder S. Mlait B.A. , M.B.A., BA, MBA, CEO & Director (Age 43) Mr....
Who are some of Cannabix Technologies' key competitors?
Some companies that are related to Cannabix Technologies include Innovative Industrial Properties (IIPR) , MassRoots (MSRT) , Canopy Growth (WEE...
What other stocks do shareholders of Cannabix Technologies own?
Based on aggregate information from My MarketBeat watchlists, some companies that other Cannabix Technologies investors own include Aurora Cannabi...
What is Cannabix Technologies' stock symbol?
Cannabix Technologies trades on the CNSX under the ticker symbol "BLO."
What is Cannabix Technologies' official website?
The official website for Cannabix Technologies is www.cannabixtechnologies.com .
How can I contact Cannabix Technologies?
Cannabix Technologies' mailing address is 7934 Government Rd, BURNABY, BC V5A 2E2, Canada . The company can be reached via phone at +1-604-5517831 .
Short Interest ()
Per-Share Earnings, Actuals and Estimates
Money flow measures the relative buying and selling pressure on a stock, based on the value of trades made on an "uptick" in price and the value of trades made on a "downtick" in price. The up/down ratio is calculated by dividing the value of uptick trades by the value of downtick trades.
BELLUS Health Reports Year 2021 Financial Results and Business Highlights
Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International stock quotes are delayed as per exchange requirements. Fundamental company data and analyst estimates provided by FactSet.
All You Need to Know About Bellus (BLU) Rating Upgrade to Buy
LAVAL, Quebec, February 23, 2022--BELLUS Health Inc.
Is BELLUS Health (TSE:BLU) In A Good Position To Invest In Growth?
Bellus (BLU) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Bellus (BLU) Stock Surges on Data From Chronic Cough Study
Just because a business does not make any money, does not mean that the stock will go down. Indeed, BELLUS Health...
BELLUS Health Announces the Launch of a Public Offering of Common Shares in Canada and the United States
Bellus Health (BLU) achieves the primary endpoint in a phase IIb study evaluating BLU-5937 for the treatment of refractory chronic cough.
Here's Why Bellus Health Is Jumping Higher Today
LAVAL, Quebec, December 13, 2021--BELLUS Health Inc.
BLU Stock Alert: The Study Data That Has BELLUS Health Blasting Higher Today
Shares of Bellus Health (NASDAQ: BLU), a clinical-stage biotechnology company, are soaring in response to positive clinical-trial data. Investors excited about the company's lead candidate BLU-5937 drove the stock 58.4% higher as of 10:30 a.m. ET on Monday.
When will Bio Rad Laboratories report results?
BELLUS Health (NASDAQ:BLU) stock is rocketing higher on Monday and it’s all thanks to data from a Phase 2b clinical trial. Source: Shutterstock This clinical trial saw it testing the effectiveness of BLU-5937 in treating refractory chronic cough. The company used 50mg and 200mg doses twice a day in patients taking part in the study.
Who is Bio Rad Laboratories?
(NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, will report financial results for the second quarter 2021 on Thursday, July 29, 2021, following the close of the market. The company will discuss these results in a conference call scheduled ...
Earnings
HERCULES, Calif., June 30, 2021--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced a partnership with Seegene, Inc., a global leader in multiplex molecular diagnostics, for the clinical development and commercialization of infectious disease molecular diagnostic products.
Analyst Research
Corporate earnings are provided from Balance Sheets, Cash Flow Statements, and Statement of Retained Earnings.
Latest Press Releases
Analyst Ratings and Earnings Estimates are provided by Zacks Investment Research.
